Menu Search
Equities

WuXi XDC Cayman Inc

2268:HKG.HS

WuXi XDC Cayman Inc

Actions
  • Price (HKD)17.94
  • Today's Change0.24 / 1.36%
  • Shares traded2.62m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 21 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.

  • Revenue in HKD (TTM)2.28bn
  • Net income in HKD304.78m
  • Incorporated2020
  • Employees1.18k
  • Location
    WuXi XDC Cayman IncNo. 11 Xinhui Ring Road, Xinwu DistrictWUXI KY1-1104ChinaCHN
  • Websitehttps://wuxixdc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.